These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35149541)

  • 1. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.
    Bolleddula J; Brady K; Bruin G; Lee A; Martin JA; Walles M; Xu K; Yang TY; Zhu X; Yu H
    Drug Metab Dispos; 2022 Jun; 50(6):837-845. PubMed ID: 35149541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and Excretion of Therapeutic Peptides: Current Industry Practices, Perspectives, and Recommendations.
    He MM; Zhu SX; Cannon JR; Christensen JK; Duggal R; Gunduz M; Hilgendorf C; Hughes A; Kekessie I; Kullmann M; Leung D; Terjung C; Wang K; Wesche F
    Drug Metab Dispos; 2023 Nov; 51(11):1436-1450. PubMed ID: 37591731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
    Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
    J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper.
    Ball K; Bruin G; Escandón E; Funk C; Pereira JNS; Yang TY; Yu H
    Drug Metab Dispos; 2022 Jun; 50(6):858-866. PubMed ID: 35149542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation.
    Walles M; Berna M; Jian W; Hauri S; Hengel S; King L; Tran JC; Wei C; Xu K; Zhu X
    Drug Metab Dispos; 2022 Jun; 50(6):846-857. PubMed ID: 35306476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Migliorati JM; Liu S; Liu A; Gogate A; Nair S; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
    Drug Metab Dispos; 2022 Jun; 50(6):888-897. PubMed ID: 35221287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.
    Baker TK; Van Vleet TR; Mahalingaiah PK; Grandhi TSP; Evers R; Ekert J; Gosset JR; Chacko SA; Kopec AK
    Drug Metab Dispos; 2024 Feb; 52(3):198-209. PubMed ID: 38123948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.
    Hariparsad N; Ramsden D; Palamanda J; Dekeyser JG; Fahmi OA; Kenny JR; Einolf H; Mohutsky M; Pardon M; Siu YA; Chen L; Sinz M; Jones B; Walsky R; Dallas S; Balani SK; Zhang G; Buckley D; Tweedie D
    Drug Metab Dispos; 2017 Oct; 45(10):1049-1059. PubMed ID: 28646080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
    Tremaine L; Brian W; DelMonte T; Francke S; Groenen P; Johnson K; Li L; Pearson K; Marshall JC
    Pharmacogenomics; 2015 Dec; 16(18):2055-67. PubMed ID: 26616152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate).
    Baran SW; Brown PC; Baudy AR; Fitzpatrick SC; Frantz C; Fullerton A; Gan J; Hardwick RN; Hillgren KM; Kopec AK; Liras JL; Mendrick DL; Nagao R; Proctor WR; Ramsden D; Ribeiro AJS; Stresser D; Sung KE; Sura R; Tetsuka K; Tomlinson L; Van Vleet T; Wagoner MP; Wang Q; Arslan SY; Yoder G; Ekert JE
    ALTEX; 2022; 39(2):297–314. PubMed ID: 35064273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders.
    Volak LP; Duevel HM; Humphreys S; Nettleton D; Phipps C; Pike A; Rynn C; Scott-Stevens P; Zhang D; Zientek M
    Drug Metab Dispos; 2023 Jul; 51(7):792-803. PubMed ID: 37041086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.
    Liu S; Shah DK
    Drug Metab Dispos; 2022 Jun; 50(6):867-878. PubMed ID: 35197311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.
    Kraynov E; Kamath AV; Walles M; Tarcsa E; Deslandes A; Iyer RA; Datta-Mannan A; Sriraman P; Bairlein M; Yang JJ; Barfield M; Xiao G; Escandon E; Wang W; Rock DA; Chemuturi NV; Moore DJ
    Drug Metab Dispos; 2016 May; 44(5):617-23. PubMed ID: 26669328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting report: oligonucleotide ADME workshop.
    Hood S; Kenworthy D; Christensen JK
    Xenobiotica; 2022 Aug; 52(8):957-961. PubMed ID: 36093882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present and future in vitro approaches for drug metabolism.
    Ekins S; Ring BJ; Grace J; McRobie-Belle DJ; Wrighton SA
    J Pharmacol Toxicol Methods; 2000; 44(1):313-24. PubMed ID: 11274898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the
    Fowler S; Brink A; Cleary Y; Günther A; Heinig K; Husser C; Kletzl H; Kratochwil N; Mueller L; Savage M; Stillhart C; Tuerck D; Ullah M; Umehara K; Poirier A
    Drug Metab Dispos; 2022 Jan; 50(1):65-75. PubMed ID: 34620695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development.
    Girish S; Martin SW; Peterson MC; Zhang LK; Zhao H; Balthasar J; Evers R; Zhou H; Zhu M; Klunk L; Han C; Berglund EG; Huang SM; Joshi A
    AAPS J; 2011 Sep; 13(3):405-16. PubMed ID: 21630127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best Practices for Microbial Challenge In-Use Studies to Evaluate the Microbial Growth Potential of Parenteral Biological Products; Industry and Regulatory Considerations.
    Zamiri C; Leiske DL; Hughes P; Kirwan JP; Der E; Cox E; Warburton R; Goss M; Weiser S; Perez-Brown J; Gopalrathnam G; Liu J; Mehta SB; Shereefa S; Specht S; Aedo SJ; Goldbach P; Jia F; Kuehnle B; Page S; Voeten L; Yi L; Zhu C
    PDA J Pharm Sci Technol; 2024 Aug; 78(4):475-500. PubMed ID: 37848203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.
    Evers R; Dallas S; Dickmann LJ; Fahmi OA; Kenny JR; Kraynov E; Nguyen T; Patel AH; Slatter JG; Zhang L
    Drug Metab Dispos; 2013 Sep; 41(9):1598-609. PubMed ID: 23792813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.
    Tibbitts J; Canter D; Graff R; Smith A; Khawli LA
    MAbs; 2016; 8(2):229-45. PubMed ID: 26636901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.